Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy

References

1. ↵
   1. Apfel SC,
   2. Asbury AK,
   3. Bril V,
   4. Burns TM,
   5. Campbell JN,
   6. Chalk CH,
   7. et al.

   (2001) Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci 189, 3–5.
2. 1. Abbott CA,
   2. Malik RA,
   3. van Ross ER,
   4. Kulkarni J,
   5. Boulton AJ

   (2011) Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34, 2220–2224.
3. 1. Davies M,
   2. Brophy S,
   3. Williams R,
   4. Taylor A

   (2006) The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 29, 1518–1522.
4. ↵
   1. Backonja MM,
   2. Serra J

   (2004) Pharmacological management part 1: better-studied neuropathic pain diseases. Pain Med 5, Suppl 1, 28–47, Review.
5. ↵
   1. Boulton AJ,
   2. Vinik AI,
   3. Arezzo JC,
   4. Bril V,
   5. Feldman EL,
   6. Freedman R,
   7. et al.

   (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28, 956–962.
6. 1. Gordois A,
   2. Scuffham P,
   3. Shearer A,
   4. Oglesby A,
   5. Tobian JA

   (2003) The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26, 1790–1795.
7. ↵
   1. Jia HY,
   2. Li QF,
   3. Song PD,
   4. AN ZM,
   5. Liu YP,
   6. Ran XW,
   7. et al.

   (2006) Effect of venlafaxine and carbamazepine for painful peripheral diabetic neuropathy: A randomized, double-blind and double-dummy, controlled multi-center trial. Chin J Evid Based Med 6, 321–327.
8. ↵
   1. Devi P,
   2. Madhu K,
   3. Ganapathy B,
   4. Sarma G,
   5. John L,
   6. Kulkarni C

   (2012) Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 44, 51–56.
9. ↵
   1. Leibson CL,
   2. Williamson DF,
   3. Melton LJ 3rd.,
   4. Palumbo PJ,
   5. Smith SA,
   6. Ransom JE,
   7. et al.

   (2001) Temporal trends in BMI among adults with diabetes. Diabetes Care 24, 1584–1589.
10. ↵
    1. Smith HS,
    2. Argoff CE

    (2011) Pharmacological treatment of diabetic neuropathic pain. Drugs 71, 557–589.
11. ↵
    1. Kamei J,
    2. Mizoguchi H,
    3. Narita M,
    4. Tseng LF

    (2001) Therapeutic potential of PKC inhibitors in painful diabetic neuropathy. Expert Opin Investig Drugs 10, 1653–1664.
12. ↵
    1. Habib AA,
    2. Brannagan TH 3rd.

    (2010) Therapeutic strategies for diabetic neuropathy. Curr Neurol Neurosci Rep 10, 92–100.
13. ↵
    1. Chong MS,
    2. Hester J

    (2007) Diabetic painful neuropathy: current and future treatment options. Drugs 67, 569–585.
14. ↵
    1. Boulton AJ,
    2. Malik RA,
    3. Arezzo JC,
    4. Sosenko JM

    (2004) Diabetic somatic neuropathies. Diabetes Care 27, 1458–1486.
15. ↵
    1. Reips UD,
    2. Funke F

    (2008) Interval-level measurement with visual analogue scales in internet based research: VAS Generator. Behavior Res Methods 40, 699–704.
16. ↵
    1. Dworkin RH,
    2. Turk DC,
    3. Wyrwich KW,
    4. Beaton D,
    5. Cleeland CS,
    6. Farrar JT,
    7. et al.

    (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9, 105–121.
17. ↵
    1. Hurley RW,
    2. Lesley MR,
    3. Adams MC,
    4. Brummett CM,
    5. Wu CL

    (2008) Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med 33, 389–394.
18. ↵
    1. Bril V,
    2. England J,
    3. Franklin GM,
    4. Backonja M,
    5. Cohen J,
    6. Del Toro D,
    7. et al.

    (2011) Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 76, 1786–1765.
19. ↵
    1. Rowbotham MC,
    2. Goli V,
    3. Kunz NR,
    4. Lei D

    (2004) Venlafaxine extended release in treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110, 697–706.
20. ↵
    1. Simpson DA

    (2001) Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscular Dis 3, 53–62.
21. ↵
    1. Lindsay TJ,
    2. Rodgers BC,
    3. Savath V,
    4. Hettinger K

    (2010) Treating diabetic peripheral neuropathic pain. Am Fam Physician 82, 151–158.
22. ↵
    1. Chakrabarti AK,
    2. Samantary SK

    (1976) Diabetic peripheral neuropathy: nerve conduction studies before, during and after carbamazepine therapy. Aust N Z J Med 6, 565–568.
23. ↵
    1. Lesser H,
    2. Sharma U,
    3. LaMoreaux L,
    4. Poole RM

    (2004) Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 63, 2104–2110.
24. 1. Richter RW,
    2. Portenoy R,
    3. Sharma U,
    4. Lamoreaux L,
    5. Bockbrader H,
    6. Knapp LE

    (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6, 253–260.
25. 1. Rosenstock J,
    2. Tuchman M,
    3. LaMoreaux L,
    4. Sharma U

    (2004) Pregabalin for treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110, 628–638.
26. ↵
    1. Freynhagen R,
    2. Strojek K,
    3. Griesing T,
    4. Whalen E,
    5. Balkennohl M

    (2005) Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomized, double-blind, multicenter, placebo-controlled trials of flexible and fixed-dose regimens. Pain 115, 254–263.
27. ↵
    1. Punay NC,
    2. Couch JR

    (2003) Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 7, 51–54.
28. 1. Storey JR,
    2. Calder CS,
    3. Hart DE,
    4. Potter DL

    (2001) Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41, 968–975.
29. 1. Rapoport A,
    2. Mauskop A,
    3. Diener HC,
    4. Schwalen S,
    5. Pfeil J

    (2006) Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache 46, 1151–1160.
30. 1. Afshari D,
    2. Rafizadeh S,
    3. Rezaei M

    (2012) A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 122, 60–68.
31. ↵
    1. Bostani A,
    2. Rajabi A,
    3. Moradian N,
    4. Razazian N,
    5. Rezaei M

    (2013) The effects of cinnarizine versus sodium valproate in migraine prophylaxis. Int J Neurosci 123, 487–493.